Outcome of Strict Patient Selection for Surgical Treatment of Hepatic and Pulmonary Metastases From Colorectal Cancer

Marín, Caridad; Robles, R; Conesa, Asunción López; Torres, Juan; Flores, Domingo Pérez; Parrilla, Pascual

doi:10.1097/dcr.0b013e3182739f5e

Cited by 23 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even after surgery, currently available data are inconclusive and disheartening. Barlow and co‐workers and Marin et al . found no difference in survival in simultaneous versus sequentially detected hepatopulmonary disease.…”

Section: Discussionmentioning

confidence: 94%

“…Between 40 and 60 per cent of patients with untreated CRC develop hepatic metastases, and 10–20 per cent develop pulmonary metastases. Following curative colorectal resection, there is a reduction in these figures, with reports in the literature varying from 8 to 30 per cent for the development of hepatic metastases and from 5 to 20 per cent for pulmonary metastases. Hepatic and pulmonary metastases can develop either in a sequential manner (isolated disease, in liver or lung) or simultaneously (presentation with metastases to both liver and lung, referred to as hepatopulmonary metastases).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Outcome after liver resection in patients presenting with simultaneous hepatopulmonary colorectal metastases

Dave

Pathak

White

et al. 2014

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Outcome after liver resection in patients presenting with simultaneous hepatopulmonary colorectal metastases

Dave

Pathak

White

et al. 2014

British Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…In patients with CRC, the early and precise detection of liver metastases offers the opportunity to perform liver-targeted therapy [2,26,27]. Nowadays, the general means of diagnosis is radioactive imaging with or without serum CEA and CA19-9 levels.…”

Section: Discussionmentioning

confidence: 99%

CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer

et al. 2016

View full text Add to dashboard Cite

IntroductionLiver is the most common site of distant metastasis in colorectal cancer (CRC). Early diagnosis and appropriate treatment selection decides overall prognosis of patients. However, current diagnostic measures were basically imaging but not functional. Circulating tumor cells (CTCs) known as hold the key to understand the biology of metastatic mechanism provide a novel and auxiliary diagnostic strategy for CRC with liver metastasis (CRC-LM).ResultsThe expression of CD133+ and CD133+CD54+CD44+ cellular subpopulations were higher in the peripheral blood of CRC-LM patients when compared with those without metastasis (P<0.001). Multivariate analysis proved the association between the expression of CD133+CD44+CD54+ cellular subpopulation and the existence of CRC-LM (P<0.001). The combination of abdominal CT/MRI, CEA and the CD133+CD44+CD54+ cellular subpopulation showed increased detection and discrimination rate for liver metastasis, with a sensitivity of 88.2% and a specificity of 92.4%. Meanwhile, it also show accurate predictive value for liver metastasis (OR=2.898, 95% C.I.1.374–6.110).Materials and MethodFlow cytometry and multivariate analysis was performed to detect the expression of cancer initiating cells the correlation between cellular subpopulations and liver metastasis in patients with CRC. The receiver operating characteristic curves combined with the area under the curve were generated to compare the predictive ability of the cellular subpopulation for liver metastasis with current CT and MRI images.ConclusionsThe identification, expression and application of CTC subpopulations will provide an ideal cellular predictive marker for CRC liver metastasis and a potential marker for further investigation.

show abstract

“…Salvage surgery already plays a role in the treatment of esophageal cancer, colorectal cancer and other tumors . In recent years, salvage surgery has also been introduced into the treatment strategy of advanced lung cancer after chemotherapy/radiotherapy failure .…”

Section: Introductionmentioning

confidence: 99%

Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series

et al. 2020

View full text Add to dashboard Cite

Background Tumor recurrence or residual tumor after targeted therapy is common in patients with advanced non‐small cell lung cancer (NSCLC). There is a lack of high‐level evidence on which type of treatment should be employed for these patients and the role of salvage surgery has not been well reported in the literature. Methods A retrospective analysis of patients who underwent salvage surgery in our center between January 2016 and June 2019 for advanced NSCLC after targeted therapy was performed. Results A total number of nine patients were identified, including five males and four females, with a median age of 56 years (range, 40–65 years), all diagnosed with lung adenocarcinoma stage IIIa–IVb. All patients had received targeted therapy according to individual positive mutation of driver gene(s). Salvage surgery was performed for tumor recurrence or residual tumor after a duration of 2–46 months of targeted therapy. A negative surgical margin was achieved in all cases. Postoperative complication rate was 11.1% (1/9). All patients were alive at the time of this analysis and two patients had disease progression. After a median follow‐up of 17 months (range: 5–44 months), the median event‐free survival and postoperative survival was 14 months (range: 2–44 months) and 17 months (range: 5–44 months) respectively. Conclusions Salvage surgery may be a feasible and promising therapeutic option for tumor recurrence or residual tumor in advanced NSCLC in selective patients after targeted therapy. Key points Salvage surgery is feasible in selected patients with advanced NSCLC and provides promising survival outcomes after targeted therapy failure. Salvage surgery provides precise molecular and pathological information which is most important for subsequent therapy.

show abstract

Outcome of Strict Patient Selection for Surgical Treatment of Hepatic and Pulmonary Metastases From Colorectal Cancer

Abstract: In patients with hepatic and pulmonary metastases from colorectal cancer selected according to strict inclusion criteria, surgical treatment performed in a specialized center is a safe option that offers prolonged survival.

Cited by 23 publications

References 33 publications

Outcome after liver resection in patients presenting with simultaneous hepatopulmonary colorectal metastases

Outcome after liver resection in patients presenting with simultaneous hepatopulmonary colorectal metastases

CD133+CD54+CD44+ circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer

Salvage surgery for advanced non‐small cell lung cancer after targeted therapy: A case series

Contact Info

Product

Resources

About